癫痫患者外周血miRNA/lncRNA的表达与生物信息学研究

注册号:

Registration number:

ChiCTR-COC-15006320 

最近更新日期:

Date of Last Refreshed on:

2015-04-30 13:37:27 

注册时间:

Date of Registration:

2015-04-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

癫痫患者外周血miRNA/lncRNA的表达与生物信息学研究

Public title:

Study on exoression and biological information of peripheral blood miRNA/lncRNA in patients with epilesy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

癫痫患者外周血miRNA/lncRNA的表达与生物信息学研究

Scientific title:

Study on exoression and biological information of peripheral blood miRNA/lncRNA in patients with epilesy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

朱玉叶 

研究负责人:

陈升东 

Applicant:

Yuye Zhu 

Study leader:

Shengdong Chen 

申请注册联系人电话:

Applicant telephone:

+86 15961111867

研究负责人电话:

Study leader's
telephone:

+86 13515270800

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

805233195@qq.com

研究负责人电子邮件:

Study leader's E-mail:

chado808@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国江苏省常州市和平北路55号

研究负责人通讯地址:

中国江苏省常州市和平北路55号

Applicant address:

55 North Peace Road, Changzhou, Jiangsu, China

Study leader's address:

55 North Peace Road, Changzhou, Jiangsu, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

解放军第102医院

Applicant's institution:

102th hospital of Chinese People’s Liberation Army

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

科伦审【2015】2015-40-1号

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

解放军第102医院医学伦理委员会

Name of the ethic committee:

Medical ethics committee of No.102 hospital of People's Liberation Army

伦理委员会批准日期:

Date of approved by ethic committee:

2015-03-17 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

解放军第102医院

Primary sponsor:

102th Hospital of Chinese People’s Liberation Army

研究实施负责(组长)单位地址:

中国江苏省常州市和平北路55号

Primary sponsor's address:

55 North Peace Road, Changzhou, Jiangsu, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

常州

Country:

China

Province:

Jiangsu

City:

Changzhou

单位(医院):

解放军第102医院

具体地址:

中国江苏省常州市和平北路55号

Institution
hospital:

102th Hospital of Chinese People’s Liberation Army

Address:

55 North Peace Road, Changzhou, Jiangsu, China

经费或物资来源:

南京军区医药卫生资金项目

Source(s) of funding:

Medical, pharmaceutical and public health fund of Nanjing Military Command Area

研究疾病:

癫痫  

Target disease:

Epilesy

研究疾病代码:

Target disease code:

研究类型:

病因学/相关因素研究

Study type:

Cause/Relative factors study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

发现癫痫致病基因,阐明癫痫分子遗传机制及病因,建立癫痫发病预测、靶向治疗、用药监测、疗效评估、预后预测及复发风险等个性化综合治疗评估系统。  

Objectives of Study:

To identify susceptible genes of epilepsy, illustrate molecular genetics mechanism of epilepsy, and establish an integrated system involving forecasting, target treatment, medication monitoring, effect evaluation, prognosis prediction and relapse risk evaluation

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.有严重情感障碍,智力发育迟滞者;
2.有严重酗酒史和药物滥用史;
3.入院前1个月有大量输血史;
4.入院前1个月曾用抗癫痫药物;

Exclusion criteria:

With history of serious emotional disorders, mental retardation; With history of severe alcoholic problem or drug abuse. With history of blood transfusion one month before inclusion; With history of anti-psychotic medication three months before inclusion.

研究实施时间:

Study execute time:

From 2015-05-01 00:00:00 To 2017-12-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2015-05-01 00:00:00 To 2015-07-31 00:00:00

干预措施:

Interventions:

组别:

癫痫组

样本量:

80

Group:

Epilesy Group

Sample size:

干预措施:

药物治疗

干预措施代码:

Intervention:

Medication

Intervention code:

组别:

正常对照组

样本量:

40

Group:

Normal control group

Sample size:

干预措施:

自然观察

干预措施代码:

Intervention:

observation

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

常州 

Country:

China

Province:

Jiangsu

City:

Changzhou

单位(医院):

解放军第102医院 

单位级别:

正团级 

Institution
hospital:

No.102 hospital of Chinese People’s Liberation Army.

Level of the institution:

Regimental level

测量指标:

Outcomes:

指标中文名:

小分子核糖核酸

指标类型:

主要指标

Outcome:

microRNA

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

长链非编码核糖核酸

指标类型:

主要指标

Outcome:

Long non-coding RNA

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

外周血

Sample Name:

blood

Tissue:

peripheral blood

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 65 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

队列研究

Randomization Procedure (please state who generates the random number sequence and by what method):

This is a cohort study.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2015-04-30 13:37:28